Exhibit at the 2019 Optometry's Meeting®

Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharma company focused on development and commercialization or products using our proprietary mucus-penetrating particle (MPP) technology. Kala is initially focused on the treatment of eye diseases. We’ve applied our MPP technology to create nanosuspensions of loteprednol etabonate, a corticosteroid designed for ocular applications, resulting in our two lead product candidates; INVELTYS for the treatment of inflammation and pain following ocular surgery. INVELTYS has a PDUFA date in late-August 2018. Our second formulation is for the temporary relief of the signs and symptoms of dry eye disease. Kala went public in 2017.

Brands: INVELTYS for the treatment of inflammation and pain following ocular surgery. INVELTYS has a PDUFA date in late-August 2018. Our second formulation is for the temporary relief of the signs and symptoms of dry eye disease.